Primitive neuroectodermal tumours (PNET) are thought to derive from the malignant transformation of pluripotent CNS precursors although this hypothesis has yet to be tested in vitro. Here we show that cells of a human PNET cell line`Dev' express functional ®broblast growth factor (FGF) receptors (FGFR) and respond to FGF2 as multipotent CNS precursors. FGF2 induces tyrosine phosphorylation of FGFR-1 and FGFR-2 and many cellular substrates including MAP kinases and stimulates proliferation. Cells detach from plastic substrates and proliferate to form large clusters of undierentiated cells. After adhesion to polylysine, cells migrate out from the clusters and dierentiate. The majority of dierentiated cells express neuronal phenotypes but distinct subpopulations express oligodendrocytic and astrocytic markers. Mature neural dierentiation markers are not otherwise detected in Dev cells in de®ned medium. Identical results were obtained with 12 monoclonal subclones as well as the parent cell line, con®rming that Dev cells are multipotent. This extends evidence that multipotent CNS precursors are the cellular substrate from which certain PNET develop and shows that FGF2 is a potent proliferation and dierentiation inducer for PNET cells in vitro, suggesting that FGF2 may also modulate the evolution of PNET in vivo. Finally our results suggest that PNET cell lines may provide models to elucidate the biology of human multipotent CNS precursors.
Introduction
Primitive neuroectodermal tumours (PNET), of which medulloblastoma is the most common, are the brain tumours that occur most frequently in children. Several lines of evidence suggest that they may be derived from pluripotent neural precursors or their immature progeny (Trojanowski et al., 1994; Valtz et al., 1991; McKay et al., 1993; Rorke et al., 1997) . Central nervous system (CNS) stem cells and multipotent precursors have been identi®ed by lineage studies using retroviral labels in vivo and in vitro as well as subcloning studies in dispersed cell cultures of developing and adult brain (Reid et al., 1995; Stemple and Mahanthappa, 1997; Qian et al., 1997) . They are capable of proliferation and dierentiation with neuronal, oligodendrocytic and astrocytic fates. Thus despite the fact that most cells in PNET are undierentiated, one of the hallmarks of PNET is that dierent subpopulations of tumour cells in the same tumour may express markers characteristic of distinct neuronal and glial phenotypes (Kleihues et al., 1993; Packer et al., 1984; Trojanowski et al., 1994) . Furthermore PNET cells are often immunopositive for nestin, an intermediate ®lament protein characteristic of undierentiated pluripotent neuroectodermal precursors (Tohyama et al., 1992; Lendahl et al., 1990) . Finally, patterns of expression of platelet derived growth factor receptor subtypes expressed in PNET tumour cells correspond to the expression of these receptors on immature neural stem cells and undifferentiated neuroblasts (Smits et al., 1996) . However, despite the apparent similarity of PNET cells to multipotent CNS stem cells in vivo, none of the several cell lines that have been prepared from PNET has been shown to be multipotent (Pietsch et al., 1994; Trojanowski et al., 1994; Rorke et al., 1997) .
We have described a cell line, Dev, derived from a cerebellar PNET (medulloblastoma), which is unique among PNET cell lines because subpopulations of Dev cells can be induced to dierentiate towards neuronal or astrocytic lineages when they are cultivated in fetal calf serum (FCS) (Dufay et al., 1994; Giraudon et al., 1993) . However, Dev cells are intrinsically undifferentiated in that they do not express mature neural markers when plated and maintained in the absence of FCS.
Basic ®broblast growth factor (FGF2) stimulates the proliferation and dierentiation of multipotent CNS stem cells by as yet unidenti®ed mechanisms (Johe et al., 1996; Vescovi et al., 1993; Gritti et al., 1996; Qian et al., 1997) and is present in FCS. FGF receptors (FGFR) have been identi®ed in undierentiated neuroepithelial cells in vivo and in vitro (Peters et al., 1993; Miyake et al., 1995) and in PNET (Weiner et al., 1996) .
Here we show that Dev cells possess functional FGFR and that FGF2 drives Dev cells to proliferate, then dierentiate, as evidenced by expression of antigens characteristic of mature neurons and glia. Such antigens are not otherwise observed in Dev cells in serum-free medium. These data provide compelling new evidence that some PNET cells share the biological characteristics of FGF2-dependent multipotent precursors and hence may derive from the transformation of such cells in human brain. Furthermore, since FGF2 drives the proliferation and dierentiation of PNET cells in vitro, FGF2 may be implicated in the etiology of PNET in vivo.
Results

Dev cells express an undierentiated neuroepithelial phenotype in serum-free medium
In previous studies we have established that Dev cells express neuronal and glial antigens when cultured in the medium containing high levels of fetal calf serum (Dufay et al., 1994; Giraudon et al., 1993) . The expression of mature cell type-speci®c antigens such as neuro®laments, GFAP or galactocerebroside is not observed when Dev cells are plated and maintained in serum free medium (EA Derrington, C Bellin, N Dufay, A Jouvet, S Bertrand, G St-Pierre and M-F Belin, submitted). Under these conditions, Dev cells express nestin (Figure 1a) , a marker characteristic of pluripotent CNS stem cells and neural precursors in vivo and in vitro, which is often expressed by PNET cells (Tohyama et al., 1992) . Anti-nestin immunoreactivity was restricted to undierentiated cells in clusters. Antibodies against MAP 5, another marker speci®c for undierentiated neural precursor cells (Williams and Price, 1995) , gave similar labelling of cells within clusters but also stained morphologically dierentiated cells on the edge of clusters (Figure 1c ). These data support the hypothesis that Dev cells express an undierentiated neuroectodermal phenotype under these culture conditions.
Dev cells express functional FGF receptors
FGF receptors comprise a family of receptor tyrosine kinase glycoproteins coded by four distinct but closely related genes (FGFR1 ± 4) each of which has several alternatively spliced forms (Green et al., 1996) . Since ®broblast growth factors are implicated in the survival, proliferation and dierentiation of multipotent CNS precursor cells we examined the expression of FGFRs in Dev cells by probing Western blots of WGA precipitates of Dev cells with anity-puri®ed antibodies against FGFR 1 ± 4 (Figure 2a ). Immunoreactive proteins of 170 kDa and 140 kDa were speci®cally recognized by antibodies against FGFR1. A band of 160 kDa was recognized only by antibodies against FGFR2. A distinct band that migrated slightly faster was recognized by antibodies against FGFR4 and bands of about 75 kDa were recognized by all the antisera, but most strongly by antibodies against FGFR3. Immunoprecipitation using each of the antibodies, followed by Western analysis with all of the anti-FGFR antibodies, con®rmed the selectivity with which anti-FGFR1 and anti-FGFR2 antibodies recognized the above immunoreactive bands. The band recognized by anti-FGFR4 in WGA precipitates did not appear to be immunoprecipitated by anti-FGFR4 antibodies. There was no cross-reactivity between the antibodies other than the 75 kDa bands which were immunoprecipitated and recognized by all of the antisera (data not shown). The 75 kDa band was also recognized by anti-FGFR3 after immunoprecipitation with an irrelevant antibody (anti-TrkA; sc-118) and is therefore not speci®c.
After treatment with FGF2 (100 ng/ml for 1, 5 or 30 min) the bands speci®cally immunoprecipitated by antibodies against FGFR1 and FGFR2 were recognized by antibodies to phosphotyrosine on Western blots (Figure 2b ). These bands were also immunoprecipitated by anti-phosphotyrosine antibodies after 5 min of stimulation with FGF2 (data not shown). The band recognized by anti-FGFR4 in WGA precipitates was neither immunoprecipitated by antiphosphotyrosine antibodies nor recognized by antiphosphotyrosine after immunoprecipitation by anti-FGFR4 in either control cultures or cultures treated with FGF2.
These data suggest that the proteins recognized by anti-FGFR1 and anti-FGFR2 are functional FGF2 receptors and that Dev cell responses to FGF2 are in part mediated via these. They do not allow us to exclude roles for the proteins recognized by anti-FGFR3 and anti-FGFR4 but clearly do not support that they function in mediating responses to FGF2 under the above conditions. Distinct FGFRs can show diering anities for various FGFs as well as varying eciencies in recruiting several second messenger pathways (Shaoul et al., 1995) . In Dev cells, treatment with FGF2 for 1, 5, or 30 min leads to the tyrosine phosphorylation of a number of cellular substrates (Figure 2c ). The phosphorylation of MAP kinases ERK1 and ERK2, which can be evidenced by their reduced migration on polyacrylamide gels, is concommitant with the activation of these kinases (Howe et al., 1992) and is a common step in second message pathways involved in transduction of both mitogenic and dierentiating signals from receptor tyrosine kinases including those for FGF (Shaoul et al., 1995; Crews et al., 1992) . Treatment with FGF2 (5 min, 100 ng/ml) leads to the slowed migration of both 42 kDa ERK2 and 44 kDa ERK1 as shown by Western blots developed with a polyclonal antibody that recognizes both phosphorylated and non-phosphorylated ERK1 and ERK2 (Figure 2d ). These MAP kinase species were also immunoprecipitated by anti-phosphotyrosine antibodies in FGF-treated cells (not shown). These data con®rm that FGF2 treatment leads to phosphorylation and activation of MAP kinases in Dev cells.
FGF2 induces proliferation and substrate detachment of Dev cells
Previous studies in vitro have shown that FGF2 can act as a mitogen for central nervous system stem cells (Johe et al., 1996) and pluripotent progenitor cells from embryonic brain (Gritti et al., 1996; Bartlett, 1993, 1995; Qian et al., 1997) . In the de®ned medium Dev cells proliferate exponentially with a (7) stained by an anti-MAP kinase antiserum that recognizes both phosphorylated and non-phosphorylated forms of ERK1 and ERK2. Non-phosphorylated ERK1 and ERK2 are indicated on the left and phosphorylated ERK1 and ERK2 (ERK1P and ERK2P) are indicated on the right population doubling time of about 5 days. Cell counts showed that FGF2 treatment of Dev cells decreased population doubling times to about 2.5 days. This suggested that FGF2 was increasing the speed of cell proliferation. Improved cell survival might also lead to reduced population doubling times therefore¯ow cytometry was performed to analyse the distribution of unsynchronized cells in the cell cycle using propidium iodide to quantitate DNA. Our results showed that after 3 days there was a signi®cant drop in G1 phase cells and increases in the proportion of cells in S, G2 and M phases in cultures treated with FGF2 compared to their controls (Table 1) . This supports the hypothesis that FGF2 induces Dev cells to proliferate more quickly.
CNS stem cells proliferating in response to FGF2 may be either substrate adherent (Johe et al., 1996) or may detach from the substrate to form nonadherent clusters and tightly packed spheres of proliferating cells (Gritti et al., 1996) . In the absence of serum, Dev cells adhere to cell culture plastic and grow as clusters of round or fusiform cells, some of which grow short ®ne processes. A minority of cells developed a morē attened epithelial morphology or were bipolar. Treatment with FGF2 (20 ng/ml) dramatically reduced the tendency of cells to form processes. This was already apparent after 15 h in culture. Over the next few days FGF2-treated cells became progressively much less adherent than controls and detached from the culture¯ask if it was shaken gently. After 3 ± 5 days, the majority of cells in FGF-treated cultures werē oating, either singly or in clusters, with cluster size increasing with time in culture. Cells could be maintained in FGF-supplemented medium as¯oating clusters for several months, although after long periods of time, larger agglomerates of cells sometimes adhered to the plastic.
Substrate adhesion induces morphological dierentiation
After 7 ± 60 days treatment with FGF2, cells were diluted in either control medium or medium enriched with FGF2 (20 ng per ml) and plated on polylysine in labtek chamber slides or in¯asks at low density (1 colony per cm 2 ). In the low density cultures, colonies formed from single clusters could be identi®ed by marking the bottom of the¯ask and their progress subsequently monitored over several weeks. Within 15 h after plating, the vast majority of cells and clusters had adhered. Adhesion was very rare if cell clusters and agglomerates were transferred to uncoated plastic in either the presence or absence of FGF2. On polylysine substrates, cells migrated out from the spheres and spread over the substrate. Proliferation appeared to continue in the core of the spheres regardless of the continued presence or removal of FGF2, which had no evident eect on the behaviour of the adherent cells. On the periphery of the spheres, cells which had migrated further away had more dierentiated morphologies. Cell death was apparent and occurred both among the more dierentiated cells on the periphery of colonies and also after longer periods in culture in the remaining core of the sphere. Single cells that adhered away from colonies did not proliferate and died during the ®rst week after plating.
When freshly prepared control cells were plated on polylysine they were identical to control cells plated on plastic with respect to morphological and immunocytochemical criteria (data not shown). When control cells were plated on plastic at very high initial densities (2610 5 cells per cm 2 ), dense clusters which were less adherent to plastic could be recovered by quite gentle pipeting after about 10 ± 14 days. These resuspended clusters closely resembled the¯oating clusters generated in FGF2. However when plated on polylysine, there was very little tendency for cells to migrate away from the core of the cluster, although some cells on the periphery did exhibit evidence of morphological dierentiation after 5 ± 10 days.
Monoclonal subclones of the Dev cell line
Although cancer is a clonal disease and tumours are thought to derive from the transformation of a single cell, multiple mutations during tumour growth may contribute to the development of distinct subclones of cells within a tumour. Previous investigations had suggested that Dev cells were capable of dierentiation towards either the astrocytic or neuronal pathways in response to exogenous stimuli (Dufay et al., 1994; Giraudon et al., 1993) . The question of whether distinct subpopulations of cells within the cell line are responding was not addressed. To determine if single cells might be pluripotent, the Dev cell line was subcloned. We found that single cells did not proliferate in the absence of serum even after addition of FGF2, or in medium conditioned by cells proliferating in the presence or absence of FGF2. These results suggested that, in de®ned medium, cells required cell-cell contact in order to proliferate. This agrees with the observations that primitive neuroepithelial cells (NE cells) could only be observed in high density cultures (Williams and Price, 1995) and that cortical neuroblasts required cell contact to be maintained in a proliferating state (Ghosh and Greenberg, 1995) . Single cells did proliferate in the presence of 20% FCS. Monoclonal subclones were generated in medium containing serum and expanded in the wells of 96 well plates until they contained several hundred cells. Clones were then extensively washed to remove serum, passaged and split into two samples which were grown in adjacent wells of 12 well plates in serum-free medium with or without FGF2 (20 ng/ml). Of 19 clones that were generated, 12 survived and grew in serum-free medium supplemented with FGF2 in a manner apparently identical to the parent cell line. All their sister clones, cultivated in the absence of FGF2 died. This suggested that FGF2 may play a role in cell survival at low cell density in the absence of FCS. The 12 surviving clones were expanded in culture for several months and transferred to polylysine coated labteks for single and double-labelling of neural antigens.
Expression of mature neural cell type-speci®c markers
Dev cells and monoclonal subclones were processed for immunocytochemistry 7 ± 15 days after plating on polylysine to analyse the expression neural antigens. Results obtained with all 12 monoclonal subclones and the parent cell line were identical. Micrographs in Figure 3 are from one subclone and the doublelabelling in Figure 4 is from a dierent subclone. In both cases cells were ®xed 15 days after plating.
In cultures that had been expanded in FGF2, about 50% of colonies contained cells stained by antibodies to neuro®lament (Figure 3a) . Immunoreactivity against neuro®lament was often concentrated in a dense structure in the cell soma. More rarely anti-neurofilament antibodies labelled processes in morpholiogically dierentiated cells on the periphery of colonies that Figure 3 Expression of neural antigens. 15 days after plating on polylysine coated wells, cells that had been grown in the presence of FGF2 prior to plating were ®xed and stained with antibodies against neural cell type-speci®c antigens. (a) and (b) show a cluster with a high proportion of neuro®lament-labelled cells. Very often labelling is con®ned to an intensely¯uorescent structure in the soma of immunolabelled cells. More rarely, and usually on the periphery of clusters, more dierentiated cells with immunopositive processes can be observed (c). Similar results were obtained with anti-MAP2 although anti-MAP2 staining was often more diuse throughout the cytoplasm (d). Whole clusters of cells were sometimes found stained with anti-galactocerebroside (e and f) but more often groups of galactocerebroside-positive cells were observed on the periphery of large clusters of unstained cells, some cells showed evidence of morphological dierentiation such as vestigial immunolabelled processes, indicated by arrows (g). GFAPpositive cells were rare and occurred scattered among clusters of other cells that were not labelled with anti-GFAP (h and i). Scale bars are 25 mm contained high proportions of neuro®lament-positive cells (Figure 3c ). Similar results were obtained with anti-MAP2 (Figure 3d) .
Colonies of cells stained by anti-galactocerebroside were rare; only one or two colonies per labtek well when cells had been seeded at higher densities and less than one colony per well at lower densities. More frequently, in about 25% of the colonies, small clusters of galactocerebroside-positive cells were scattered among unstained cells at the periphery of unstained colonies. Galactocerebroside-positive cells were usually round or polygonal (Figure 3e ) although some developed vestigial processes or were bipolar (Figure 3g) . Similar results were obtained with anti-O4.
Cells stained by anti-GFAP were very rare and usually only ®ve or ten cells were stained in or around any given colony and only in about one colony in ten. GFAP-labelled cells often appeared to be¯at or fusiform and were scattered in a region or on the periphery of colonies of unstained cells (Figure 3h ). Double-labelling showed that cells, did not coexpress aberrant combinations of neuronal and glial markers (Figure 4 ), indeed few colonies contained cells expressing two distinct neural cell types. Colonies containing both galactocerebroside-and GFAPlabelled cells were not observed. In some cases cells that had died prior to ®xation were stained by antibodies against neural cell type-speci®c antigens (Figure 4) . Although dead cells can sometimes give non-speci®c staining, the fact that markers of distinct cell types did not co-localize in such cells strongly implies that their labelling was speci®c under the conditions we used. No dierence was observed between cultures that were maintained in the presence of FGF2 after plating on polylysine and cultures from which FGF2 was removed.
In some experiments cells of the parent cell line were grown in the same medium except that FGF2 was replaced by either EGF (5 ± 50 ng/ml), PDGF AA (5 ± 20 ng/ml), CNTF (5 ± 50 ng/ml), NGF (20 ng/ml), BDNF (20 ng/ml) or NT3 (20 ng/ml) for 7 or 14 days prior to cells being transplanted to polylysine coated labtek wells. Cells were then maintained in culture for another 10 days in either the presence or absence of the same growth factors. Immunocytochemistry showed no evidence of the expression of neural cell type-speci®c antigens (data not shown).
A previous study reported that CNTF or T3 increases the proportions of neural stem cells expressing glial phenotypes (Johe et al., 1996) therefore in some experiments T3 (3 ± 15 ng/ml) or CNTF (5 ± 15 ng/ml) were added to cultures of¯oating clusters in the presence of FGF2 2 days before they were plated on polysine and for the next 7 days after plating (as described Johe et al., 1996) . Immunocytochemical analysis showed no eect of treatment with T3 or CNTF on the proportions of cells expressing the dierent neural phenotypes as compared with parallel cultures treated only with FGF2 (data not shown).
Discussion
The Dev cell line was prepared from a cerebellar medulloblastoma, the most frequently occurring type of PNET. Cytogenetic analysis shows that deletions of 17p and isochromosome 17q occur in 30 ± 50% of medulloblastoma and are the most frequent chromosomal abnormality in this type of tumour, although these abnormalities are not observed in other types of PNET (Biegal et al., 1989; Bigner et al., 1988; Burnett et al., 1997) . Certain inherited diseases, such as nevoid basal cell carcinoma syndrome, can predispose patients to the development of PNET and result from deletions in chromosome 9q22 (Hahn et al., 1996; Johnson et al., 1996) . Although several stem cell chromosomal abnormalities occur in Dev cells chromosome 17 and chromosome 9 appear to be normal (EA Derrington, C Bellin, N Dufay, A Jouvet, S Bertrand, G St-Pierre and M-F Belin, submitted). Stem cell lesions in Dev cells appear to concern unidenti®ed additions to the distal regions of chromosomes 2q and 4q. Double minutes are observed that result from ampli®cation and/or fragmentation of chromosome 13. Interestingly gains in chromosomes 2, 4 and 13 have been reported in PNET and medulloblastoma (Schutz et al., 1996) or in medulloblastoma cell lines previously (Pietsch et al., 1994; Bigner et al., 1988) .
PNET cells are usually undierentiated, however, evidence of dierentiation of distinct tumour cell populations towards dierent neuroectodermal lineages in the same tumour is a speci®c characteristic of PNET. This has fuelled speculation that PNET may derive from the transformation of multipotent neural precursors (Tohyama et al., 1992; Trojanowski et al., 1994; Valtz et al., 1991; Rorke et al., 1997) . The Dev cell line is unique among PNET cell lines because Dev cells may express either neuronal or glial phenotypes when cells are cultivated in medium containing FCS (Dufay et al., 1994) . Markers of mature neural cells, however, are not found in Dev cells when they are cultivated in the absence of serum. This suggests that the expression of mature neural cell type-speci®c markers occurs in response to extrinsic factors present in FCS. FGF2 is present in FCS and here we have shown that Dev cells express functional FGF receptors. FGF2 induces Dev cells to proliferate and detach from plastic substrates forming clusters and spheres of proliferating undierentiated cells. Polylysine provided an adherent substrate which allowed FGF2-treated Dev cells to migrate out from the dense spheres and dierentiate morphologically and by the expression of markers of the distinct mature neural cell types. This response to FGF2 is typical of that reported for pluripotent neuroectodermal stem cells (Gritti et al., 1996) . To test whether Dev cells are indeed pluripotent 12 monoclonal subclones of the Dev cell line were prepared, expanded in FGF2 and analysed for the expression of neural markers. Distinct cells populations in all the clones expressed neuronal, astrocytic and oligodendrocytic markers after plating on polylysin. Our data support that the Dev cell line is composed of transformed pluripotent neuroectodermal progenitors and their progeny.
Cells expressing neuronal markers were observed more frequently under these conditions than cells expressing glial markers. This agrees with previous results that undierentiated neuroectodermal precursors may require higher concentrations of FGF2 or treatment with FCS or conditioned medium for expression of glial phenotypes (Kilpatrick and Bartlett, 1993; Qian et al., 1997) and may also re¯ect the observation that glial phenotypes are rarely observed in PNET and PNET cell lines. It is also interesting that oligodendrocytic markers have not been reported in PNET biopsy specimens although they have been detected in other PNET cell lines (Pietsch et al., 1994) . Perhaps technical diculties in staining the glycolipid antigens that specify immature oligodendrocytes may partially explain this.
FGF2 provided a mitogenic stimulus to Dev cells in the absence of serum, but only when cell-cell contact occurred. This was illustrated by our failure to produce monoclonal subclones of Dev cells in the absence of serum and by the death of isolated cells when clusters were plated on polylysine. A similar requirement of multipotent precursors for both soluble factors and cell contact for proliferation and survival has been reported previously (Williams and Price, 1995; Ghosh and Greenberg, 1995) .
FGF2 also clearly played a signi®cant function in Dev cell dierentiation. The expression of markers of mature neural cells was not observed in Dev cells unless they had been expanded in FGF2. This clearly implies that FGF2 acts not only in the proliferation of Dev cells, but also in inducing a more dierentiated state. As yet, this state can only be de®ned as the potential to express neural phenotypes after adhesion on polylysine. This result agrees with previous observations showing that FGF2 is implicated in fate determination of multipotent neural precursor cells (Vescovi et al., 1993; Qian et al., 1997) . Furthermore, none of a series of growth factors including EGF, PDGF, CNTF, NGF, BDNF and NT3 could substitute for FGF2 under the culture conditions tested.
Studies in primary culture have allowed signi®cant advances in the characterization of multipotent neural precursors. However there are limits on the amount of material that can be prepared from animal brain. To prepare homogenous populations of precursors mixed cultures must be maintained in the presence of the precursor cell mitogens. For these reasons, there is a lack of data concerning the molecular mechanisms of action of growth factors such as FGF2 on multipotent neural precursors.
Despite the problems inherent to extrapolating data gained from the study of tumour cell lines and applying them to normal cells or developmental processes, tumour cell lines have often proved important model systems in which to characterize cellular responses to growth factors (e.g. the PC12 cell line and NGF; reviewed Kaplan and Stephens, 1994: neuroblastoma cell lines and BDNF; Kaplan et al., 1993) . Dev cells respond to FGF2 in a manner which is extremely similar to that described for pluripotent stem cells and multipotent precursors. Our results suggest that FGF2 is required, not only to drive the proliferation of these cells, but to prime them for neural dierentiation after substrate adhesion. The Dev cell line provides a unique opportunity to characterize the cellular mechanisms of action of growth factors such as FGF2 on human cells in these two processes. This may be of increasing importance since the demonstration that multipotent precursors can be maintained and expanded in vitro prior to grafting and integration to adult brain (Gage et al., 1995) , which suggests that FGF-responsive precursors could be used in the treatment of neuropathologies.
Pluripotent neuroectodermal cells have yet to be identi®ed in human brain. Nevertheless it has been proposed that PNET, the most common and one of the most devastating brain tumours of infancy, may derive from the transformation of pluripotent CNS stem cells (Tohyama et al., 1992; Trojanowski et al., 1994; Valtz et al., 1991; Rorke et al., 1997) . Our data support this hypothesis and further demonstrate that FGF2, the trophic factor most intimately implicated in the control of the proliferation and dierentiation of primary neural stem cells or multipotent CNS precursors, stimulates the proliferation and dierentiation of PNET cells in vitro in a very similar manner. This suggests that improved characterization and understanding of the biology of CNS stem cells could lead to a better understanding of PNET and that PNET cell lines may provide invaluable models to study the mechanisms of action of environmental stimuli such as trophic factors in the control of proliferation, dierentiation and survival of human central nervous system precursors in vitro.
Materials and methods
Antibodies and growth factors
Anity puri®ed antibodies against FGF receptors 1-4 (sc-121, sc-122, sc-123 and sc-124) and PY20 anti-phosphotyrosine were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). 4G10 anti-phosphotyrosine was purchased from Upstate Biotechnology Inc (Lake Placid, NY). Monoclonal antibodies against neuro®lament were 2F11 (Dako, Copenhagen, Denmark) and N52 (Sigma, St. Louis, MO). Monoclonal anti-GFAP, clone GA5, was from Boehringer Mannheim, (Mannheim, Germany), or Sigma; polyclonal anti-GFAP was from Sigma. Anti-MAP5 (clone AA6) and anti-MAP2 (clone HM-2) were from Sigma. Monoclonal anti-galactocerebroside was from Boehringer Mannheim. Polyclonal anti-nestin antiserum (Tohyama et al., 1992) was donated by RDG McKay, (NIH, Bethesda, MA) and rabbit anti-MAP-Kinase (Dubois et al., 1996) was a gift from PM Dubois (CNRS-UMR-49, Ecole Normale SupeÂ rieure, Lyon, France). Monoclonal anti-O4 was donated by B Zalc (INSERM U 134, Hopital de la Salpetriere, Paris, France). Antibodies against neural cell type-speci®c antigens were evaluated for speci®city by immunocytochemistry on sections of rat brain. All gave appropriate staining of neurons and glia. FITC-conjugated goat anti-mouse IgG1 and IgG3 and Cy-3-conjugated goat anti-mouse IgG1 and goat anti-rabbit IgG were from Caltag (San Francisco, CA). FITC-conjugated swine antirabbit immunoglobulin, biotin-conjugated rabbit antimouse IGM and FITC-conjugated streptavidin were from Dako. Human recombinant FGF2 was obtained from either Sigma or Genzyme, (Cambridge, MA), other human recombinant growth factors (EGF, PDGF AA, CNTF, NGF, BDNF and NT3) were obtained from Genzyme. Thyroid hormone triiodothyronine (T3) was donated by K Gauthier, CNRS-UMR-49, Ecole Normale SupeÂ rieure, Lyon, France.
Cell culture
Dev cells, obtained from Neurobiotec (Lyon Neurological Hospital, Lyon, France), were routinely maintained in RPMI 1640 glutamax 1 medium supplemented with 20% fetal calf serum and gentamycin (all from Gibco, Gaithersburg, MD). Cells were transferred to serum free medium by resuspending in 1 mM EDTA in PBS and washing three times by resuspension and centrifugation in RPMI 1640 medium containing insulin 5 mg/ml; transferrin 5 mg/ml; and sodium selenite 5 ng/ml (Boehringer Mannheim). Cells were then plated in this medium in 25 cm 2 or 75 cm 2 tissue culture¯asks or in 6 well culture plates (all from Corning Costar Corporation, Acton, MA) at 2610 4 cells/cm 2 . Human recombinant FGF2 (20 ng/ml) was added either immediately or after 15 ± 72 h, no dierence between these conditions was observed. Control cultures did not receive FGF2. FGF2 was replaced in cultures every 3 ± 5 days. FGF2 treated cells were non-adherent to cell culture plastic and when cells became detached they were progressively diluted (1/4) in fresh medium containing FGF2 every 5 ± 7 days. Control cells in the same medium without FGF2 were adherent and medium was replaced in control cultures at the same time as in their FGF-treated sister cultures. Whereas FGF2-treated cultures could be maintained for long periods of time (at least several months) control cultures could only be maintained for several weeks before large amounts of cell death occurred. Cell survival in control cultures was not noticeably improved by changing the medium more or less frequently. Cell counts were performed (three cultures each for FGF and control for each time point) by pooling nonadherent with adherent cells after resuspending the latter in PBS EDTA (1 mM). Cells in each culture were counted in triplicate using a haemocytometer.
Subclones
Despite several attempts, we never succeeded in producing monoclonal subclones of Dev cells in the de®ned medium, in the absence of serum, with or without FGF. Single cells in the absence of serum in 96 well plates failed to proliferate and, after varying amounts of time (3 ± 15 days), died. Therefore to produce monoclonal subclones Dev cells were plated in 20% serum at 1 cell per 10 wells in 96 well plates. It was rigourously controlled that only one cell was present in wells at the start of the experiment and that only a single colony was present during the next seven days, otherwise clones were discarded. Clones were expanded in the same wells in medium containing FCS (20%) until they contained several hundreds of cells (2 ± 3 weeks). Clones were washed three times 30 min with serum-free medium then resuspended in PBS EDTA, washed once in 5 ml of serum-free medium, split into two samples and plated in 12 well plates in serum-free medium with and without FGF2 (20 ng/ml). Twelve monoclonal subclones were generated that grew in serum-free medium enriched with FGF2 (20 ng/ml) for up to several months. These were analysed by single or double-labelling of neural antigens after transfer to polylysine coated labtek slides. None of their sister control cultures survived in medium without FGF2.
Flow cytometry
Cells were resuspended with PBS EDTA and diluted to 10 6 cells/ml and samples containing 5610 5 cells were collected by centrifugation and incubated for 30 min at room temperature in 100 ml of PBS containing saponin (Sigma) 0.3% and BSA 5%, including 10 mg/ml propidium iodide and 50 U/ml RNAase (both products from Sigma) for 30 min. Cell staining was analysed using a Coulter Pro®lē ow cytometer with an argon laser (488 nm wavelength) and 515 and 615 nm ®lters. The percentage of cells in G1, S and G2/M phase were computed on the basis of their DNA content measured by propidium iodide¯uorescence intensity using M cycle software (Coulter).
Protein analysis
± 2610
6 cells were treated with FGF2 (100 ng/ml) for 0 (control), 1, 5 or 30 min and were lysed in 1 ml of 1% Nonidet P-40 lysis buer (20 mM Tris pH 7.4, 137 mM NaCl, 10% glycerol, 1 mM phenylmethylsulphonyl¯uoride, 0.15 U/ml aprotinin, 1 mM pepstatin A, 1 mM sodium vanadate, 1 mM EDTA, 1 mM EGTA, 1 mM b glycerophosphate, 1 mM levamisol, 1 mM NaF) at 48C for 20 min. Insoluble material was removed by centrifugation at 10 000 g for 10 min at 48C. Lysates were either boiled in SDS sample buer (®nal concentration 2% SDS, 10% Glycerol, 1% b mercaptoethanol, 0.25% bromophenol blue) or treated by immunoprecipitation or wheat germ agglutinin (WGA) anity puri®cation. Whole cell lysates were separated on 12.5% SDS gels to evaluate the phosphorylation of MAP kinases ERK1 and ERK2 by electrophoretic mobility, as described (Billon et al., 1997) . Immunoprecipitation with antibodies against FGF receptors (diluted 1/100), or antibodies against phosphotyrosine (4G10 or PY20) (diluted 1/100) was carried out in cell lysis buer for 1 ± 2 h at 48C and collected with protein A sepharose (Pharmacia, Uppsala, Sweden). Precipitation with WGA agarose (Pharmacia) was carried out for 1 h in the same buer using 50 ml of a 50% suspension of WGA (Pharmacia) per ml of lysate. Precipitates were washed three times with 1% Nonidet P-40 lysis buer and boiled 3 min in SDS sample buer and separated on 7.5% SDS polyacrylamide gels. Proteins were transferred to Immobilon PVDF membranes (Millipore, Bedford, MA) and after a preincubation for 30 min in 5% BSA 0.2% Tween 20, probed with antibodies against FGF reeptors or phosphotyrosine diluted in 1% BSA, 0.2% Tween 20 overnight. Blots were analysed by second incubations for 1 h at 228C with peroxidase-conjugated donkey antibodies directed against the primary antibodies diluted in the same buer. Bound peroxidase was revealed using an ECL chemiluminescence kit (Amersham, Little Chalfont, Buckinghamshire, England).
Immunocytochemical analysis
For immunocytochemistry cells were transferred to eight or four well labtek chamber slides (Nunc, Naperville, IL) that had been pre-coated for 30 min at room temperature with polylysine (20 ng/ml) at densities of 10 ± 50 clusters per well. These were maintained in culture for 10 ± 20 days with or without FGF (20 ng/ml). Medium was changed every 3 ± 5 days. Slides were ®xed with 2% paraformaldehyde at 48C for 30 min. After three washes in PBS, cells were incubated for 30 min in a solution of PBS containing 5% BSA and 1% normal goat serum prior to staining with anti-galactocerebroside or anti-O4, or PBS with 5% BSA, 1% goat serum and 0.2% Tween 20 for all other antibodies. Monoclonal primary antibodies, except anti-galactocerebroside and anti-O4, were diluted at 1/200 in PBS containing 1% BSA 1% goat serum and 0.2% Tween 20 and incubated for 2 h. The anti-galactocerebroside and anti-O4 were diluted to 1/50 in the same solution without Tween 20. Bound antibodies were revealed with FITC-conjugated goat anti-mouse IgG1 antibodies except anti-galactocerebroside which was revealed with FITC-conjugated goat anti-mouse IgG3 and anti-O4 which was revealed by biotin-conjugated rabbit anti-mouse IgM followed by streptavidin FITC. For double-labelling of galactocerebroside and either neurofilaments or GFAP sections were ®rst developed with antigalactocerebroside and then permeabilized and developed with monoclonal anti-neuro®laments or monoclonal anti-GFAP the latter antibodies being revealed using a Cy3-conjugated anti-mouse IgG1 antibody. For double-labelling of neuro®laments and GFAP sections were developed with monoclonal anti-neuro®laments revealed by Cy3-conjugated goat anti-mouse IgG1, followed by a rabbit polyclonal anti-GFAP antibody revealed with an FITCconjugated swine anti-rabbit IgG antibody. In this last case non-immune goat serum was replaced by non-immune pig serum. Controls included no primary antibody and no second primary antibody. Slides were washed three times in PBS mounted with moviol and observed with an Axiophot uorescence microscope.
